|
The Directorate General of Trade Remedies (DGTR), under the Union Ministry of Commerce & Industry, has announced an oral hearing in the ongoing anti-dumping investigation concerning the imports of monoisopropylamine (MIPA) originating in or exported from China, in accordance with Rule 6(6) of the Anti-Dumping (AD) Rules, 1995.
The proceedings aim to ascertain whether imports of MIPA from China have been unfairly priced and if they are causing material injury to the Indian market.
MIPA is a crucial chemical compound used in the synthesis of active pharmaceutical ingredients (APIs) and various drug formulations.
The investigation, which was initiated on December 30, 2024, is being conducted under the Customs Tariff Act, 1975, which govern the identification, assessment, and collection of anti-dumping duties and determination of injury to the domestic industry.
The DGTR has scheduled a public oral hearing for July 16, 2025 at 3:00 PM (IST). The hearing will be conducted in a hybrid format, allowing participants to join either physically at the DGTR conference room in Jeevan Tara Building, New Delhi, or virtually through Digital Video Conferencing (DVC).
The list of registered interested parties eligible to attend the hearing has been made publicly available on the DGTR’s official website. All participating parties are required to submit their attendance details—including organizational affiliation, contact information, and preferred mode of attendance on or before July 15, 2025.
Additionally, as per sub-para (viii) of Para 2 to the Trade Notice No.1/2009 dated March 25, 2009, it is hereby clarified that if any interested party intends to present any document in a public hearing, a copy of the same must be provided to all participants at least one day prior to the hearing.
However, in case an interested party intends to present some information on confidential basis, a copy of the same along with the non-confidential version (NCV) thereof must be submitted to the
Designated Authority at least three days prior to the date of public hearing. It should be ensured that the NCV conveys a meaningful summary of the confidential version.
In the event of non-compliance with the above requirement, the concerned interested party may not be permitted to submit or present the information on a confidential basis.
Interested parties will be required to make written submissions and the rejoinders (confidential and non- confidential version) of the views expressed at the hearing and file a rejoinder, if any, within the date and time communicated at the end of the hearing. Interested parties are advised to submit their written submissions and rejoinder, if any, to the following email addresses: <dir13-dgtr@gov.in>, <ad12-dgtr@gov.in> with a copy to <dir15-dgtr@gov.in>, <consultant-dgtr@nic.in>. The non-confidential submissions should be circulated through email by the registered interested parties to other registered interested parties.
|